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mu opioid receptor
JNK
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NF-κBDespite its potential side effects of addiction, tolerance and withdrawal symptoms, morphine is widely used for
reducing moderate and severe pain. Previous studies have shown that the analgesic effect of morphine depends
on mu opioid receptor (MOR) expression levels, but the regulatory mechanism of MOR is not yet fully under-
stood. Several in vivo and in vitro studies have shown that the c-JunNH2-terminal kinase (JNK) pathway is closely
associatedwith neuropathic hyperalgesia,which closely resembles the neuroplastic changes observedwithmor-
phine antinociceptive tolerance. In this study, we show that inhibition of JNK by SP600125, its inhibitory peptide,
or JNK-1 siRNA inducedMOR at bothmRNA and protein levels in neuronal cells. This increase inMOR expression
was reversed by inhibition of the p38mitogen-activated protein kinase (MAPK) pathway, but not by inhibition of
the mitogen-activated protein/extracellular signal-regulated kinase (MEK) pathway. Further experiments using
cell signaling inhibitors showed that MOR upregulation by JNK inhibition involved nuclear factor-kappa
B (NF-κB). The p38 MAPK dependent phosphorylation of p65 NF-κB subunit in the nucleus was increased by
SP600125 treatment. We also observed by chromatin immunoprecipitation (ChIP) analysis that JNK inhibition
led to increased bindings of CBP and histone-3 dimethyl K4, and decreased bindings of HDAC-2, MeCP2, and
histone-3 trimethyl K9 to the MOR promoter indicating a transcriptional regulation of MOR by JNK inhibition.
All these results suggest a regulatory role of the p38 MAPK and NF-κB pathways in MOR gene expression and
aid to our better understanding of the MOR gene regulation.
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Opiate drugs exert their effects through three major types of
opioid receptors: mu, delta and kappa [1]. These receptors in the
brain are activated by endogenous peptides such as enkephalins,
dynorphins and endorphins, which are released by neurons. Opioid
receptors can also be activated by exogenous alkaloid opiates, the
prototype of which is morphine, which remains the most valuable
painkiller in contemporary medicine. Although the three opioid
receptor genes are highly homologous in their coding exons, their
amino-terminal and caboxy-terminal ends are diverse, and these re-
gions govern the unique ligand-binding and signal transduction prop-
erties of each receptor [2]. Experiments with transgenic and knockout
mice have clearly demonstrated the role of mu opioid receptor (MOR)
in morphine's pharmacological effects, including analgesia, physical
dependence, and tolerance [3–5].
The mouse gene that encodes MOR (oprm1) is located on chromo-
some 10 and covers a length of 250 kilobases (kb). MOR transcription
can start from the distal promoter (DP) or the proximal promoter
(PP) [6]. PP transcripts are preferentially used in most tissues and cul-
tured cells and account for most MOR activity. The DP and PP are both
TATA-less and GC-rich, and they contain binding sites for multiple
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[9,10], PU.1 [11,12], PCBP [13], SP1 [14], AP2 [14–17], NF-κB [18], and
CREB [19]. In addition to the DP and PP, the mouse gene also uses a
TATA-containing promoter known as E11, located more than 10 kb
upstream of the translation start site [1]. Several studies have
shown that transcription of the MOR gene can be regulated by fenta-
nyl, morphine, interleukin-1, lipopolysaccharide, protein synthesis
inhibitors (cycloheximide, anisomycin and puromycin), dopaminer-
gic drugs, histone deacetylase inhibitors, and demethylating agents
[19,20]. However, the molecular events that lead to changes in MOR
gene expression have just begun to be explored.
JNK (c-Jun NH2-terminal kinase), a serine threonine protein kinase, is
amember of themitogen-activated protein kinase (MAPK) family and in-
cludes three genes, jnk1, jnk2, and jnk3. JNKs are a type of stress-activated
protein kinase (SAPK), and can be activated by various cellular stresses
such as heat shock, DNA damage, a rise in intracellular reactive oxygen
species and calcium inﬂux, neurodegeneration, and proinﬂammatory cy-
tokines (such as tumor necrosis factor-alpha[TNF-α], interleukin-6 [IL-6],
interleukin-1beta [IL-1β], interferon-gamma [IFN-γ]) [21]. JNKs have
been implicated in processes such as oncogenic transformation, apopto-
sis, and neurodegeneration [22]. Of the three JNK members, JNK-3 is
predominantly found in the brain and has different functions than
JNK-1 and JNK-2. SP600125 (SP) is an anthrapyrazole and a reversible
ATP-competitive inhibitor of JNK-1, JNK-2 and JNK-3; it has been suc-
cessfully used in vivo and in vitro to block JNK activation [23].
Chronic morphine treatment has been shown to activate JNK in
SH-SY5Y cells [24,25], T cells [26], and spinal cord [27]. In a rat model,
single or chronic morphine injections induce JNK-3mRNA in the frontal
cortex and after cessation ofmorphine treatment, sustained elevation of
JNK-3 mRNA expression occurs in the hippocampus and thalamus [28].
Moreover, MOR desensitization and acute analgesic tolerance to mor-
phine and related opiates were blocked by JNK inhibition [27,29]. In
L5-spinal nerve ligation pain models, transient JNK activation increases
in dorsal root ganglion (DRG) neurons followed by a persistent activa-
tion in spinal astrocytes which contributes to the maintenance
of neuropathic pain symptoms [21,30]. In these animal pain models,
selective inhibition of JNK inhibits mechanical allodynia and heat
hyperalgesia [30,31]. Collectively, these results suggest a role for JNK
in the pharmacological effects of nociception and opioid systems. In
our previous efforts to identify the signaling events in transcriptional
activation of the MOR gene, we observed that SP treatment of P19
cells signiﬁcantly increases MOR mRNA expression [20]. In this study,
we investigate the molecular mechanism that leads to expression of
the MOR gene upon JNK inhibition.
2. Materials and methods
2.1. Materials
SP600125 (SP), cell-permeable JNK inhibitor, and 6-amino-4-(4-
phenoxyphenylethylamino)quinazoline (QNZ) were purchased from
EMD Biosciences (San Diego, CA). 2,(4-morpholinyl)-8-phenyl-4H-
1-benzopyran-4-one (LY294002 (LY)), wortmannin and 1,4-diamino-
2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126) were
purchased from Cell Signaling Technology (Beverly, MA). 4-(4-
ﬂurophenyl)-2-(4-methylsulﬁnylphenyl)-5-(4-pyridyl)imidazole
(SB203580 (SB)), actinomycin-D (act-D), andpyrrolidine dithiocarbonate
(PDTC) were purchased from Sigma (St Louis, MO). Anti-MOR antiserum
was generated in rabbits by injecting GST-fused MOR protein containing
amino acids 340–398 of the MOR C-terminus. The speciﬁcity of
the antiserum was conﬁrmed in ﬂow cytometry analysis of HEK
293 T cells and P19 cells stably expressing MOR. Anti-phospho-c-Jun,
anti-phospho-SAPK/JNK, anti-JNK-1, anti-phospho-p38 MAPK, anti-p38
MAPK, anti-phospho-AKT, anti-AKT, anti-phospho p42/p44 MAPK,
anti-p42/44 MAPK, anti-phospho-p65 (Ser 536), anti-phospho CREB,
anti-phospho MSK1 (Thr 581) antibodies were obtained from CellSignaling Technology (Beverly, CA). Anti-c-Jun, anti-c-fos, anti-p65,
anti-phospho-p65 (Ser 276), and anti-p50 were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho serine an-
tibodies and anti-CREB were obtained from Millipore (Billerca, MA).
Anti-histone-dimethyl lysine 4 and anti-histone-trimethyl lysine 9
antibodies were obtained from Abcam (Cambridge, MA). Alkaline
phosphatase-conjugated goat anti-rabbit and goat anti-mouse IgG
were supplied by BioRad (Hercules, CA). Alexa Fluor 488-conjugated
goat anti-rabbit were purchased from Invitrogen (Carlsbad, CA). Other
reagents for molecular studies were supplied by Sigma Chemicals
(St. Louis, MO).
2.2. Cell culture and transfection
P19 cells were cultured and differentiated as described previously
[32]. For treatments, 5 × 105 cells were seeded into each wells of a
6-well plate one day before treatment. Cells were treated for 6 h
with SP (25 μM), SB (25 μM), LY (25 μM), U0126 (10 μM) and QNZ
(10 nM), and total RNA was harvested for RT-PCR. For transfection,
1 × 105 cells were seeded in 12-well dishes and co-transfected the
next day for 24 h with the MOR promoter construct and a one-ﬁfth
molar ratio of pCH110 (for β-galactosidase assay) using effectene
transfection reagent (Qiagen, Valencia, CA) as described previously
[10]. Cells were treated with SP for 12 h, and cell lysates were analyzed
for ﬁreﬂy luciferase activity and β-galactosidase activity as described
by the manufacturer's protocol (Promega and Tropix, respectively).
Results were expressed as relative luciferase activity compared to the
control cells. For siRNA transfection, cells were seeded as above and
transfected on the following day with 50 nM of control siRNA, JNK-1
siRNA, JNK-2 siRNA (Santa Cruz, CA) or SignalSilence NF-κB p65 siRNA
(Cell Signaling Technology) using Lipofectamine 2000 transfection re-
agent (Invitrogen, Carlsbad, CA) as suggested by the manufacturer's
protocol. After 36 h of transfection, cells were treated as required and
harvested for western blotting and RT-PCR. NMB neuroblastoma cells
were cultured in RPMI 1640 medium (Gibco, Grand Island, NY)
containing 10% heat-inactivated fetal bovine serum (FBS) (Hyclone,
Logan, UT), and HEK 293 T cells were cultured in advanced DMEM
medium containing 5% FBS supplemented with Glutamax (Gibco,
Invitrogen). Cells were maintained at 37 °C in a humidiﬁed incubator
and sub-cultured every 2–3 days as required.
2.3. RT-PCR and real-time quantitative RT-PCR (qRT-PCR)
Total RNA was extracted using TRI Reagent (Molecular Research
Center, Cincinnati, OH) and analyzed by RT-PCR using the MOR
gene-speciﬁc primers mMOR-S and mMOR-AS [32]. Semi-quantitative
RT-PCR was performed in 200 ng–1 μg of total RNA using a Qiagen
OneStep RT-PCR kit (Valencia, CA). Similar reactions were performed
using β-actin as an internal control [32]. qRT-PCR was performed as
described previously [33] using the same MOR primer set and the
Quantitect SYBR Green RT-PCR kit (Valencia, CA). Relative mRNA
expression was analyzed as described previously [32]. The number of
target molecules was normalized against that obtained for β-actin,
used as an internal control. The speciﬁcity of qRT-PCR primers was de-
termined using a melt curve after the ampliﬁcation to show that only a
single species of PCR product resulted from the reaction. The PCR prod-
ucts were also veriﬁed on an agarose gel. The RT-PCR and qRT-PCR
experiments were repeated at least three times to obtain statistical
signiﬁcance.
2.4. Western blotting and immunoprecipitation
Western blotting was performed as previously described [20].
4 × 105 cells were seeded into each well of 6-well dishes and treated
as required. Cells were washed twice with ice-cold phosphate buff-
ered saline (PBS) and lysed in buffer composed of 50 mM Tris–Cl,
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ase inhibitor cocktail, and phosphatase inhibitors. Cell lysates were
clariﬁed by centrifugation, and protein concentrations were deter-
mined using BCA protein assay (Thermo Scientiﬁc, Rockford, IL).
30 μg of each lysate was loaded into SDS-polyacrylamide gels and
electrotransferred onto polyvinyldiﬂuoride membranes. Membranes
were blocked for 1 h in SuperBlock solution (Thermo Scientiﬁc, Rockford,
IL) and then incubated with antibodies overnight at 4 °C with gentle
shaking as suggested by the manufacturers. Membranes were washed
3× with T-TBS (Tris buffered saline containing 0.05% Tween-20) and
incubated with alkaline-phosphatase conjugated secondary antibodies
for 1 h at room temperature. Data were collected on a PhosphorImager
with appropriate settings for each antibody. Band densities were ana-
lyzed using the ImageQuant software (GE Healthcare life sciences).
For nuclear and cytosolic protein preparations, cells were washed
and collected by scraping in cold PBS. Cytosolic protein fraction was
prepared by lysing the cells in hyopotonic lysis buffer (10 mM
HEPES, 10 mM KCl, 0.1 mM EDTA, 0.5% NP-40, 1 mM DTT, 0.5 mM
PMSF, and protease inhibitor cocktail). After centrifugation, superna-
tants were collected as cytosolic protein fractions, and nuclear pellets
were resuspended in hypertonic buffer solution (20 mM HEPES,
400 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and protease
inhibitor cocktail), vortexed vigorously, and stored on ice for 30 min.
After removing insoluble particles by centrifugation, a BCA protein
assay was performed to determine the protein yield. 20 μg of each frac-
tion was used to perform western blotting as described above.
For immunoprecipitation reactions, 1 μg antibodies were incubated
to protein G Dynabeads (Invitrogen,CA) for 4 h at 4 °C. The beads were
washed thrice with PBS and added to 300 μg of nuclear extracts pre-
pared as above, and incubated overnight on a rotating platform at
4 °C. On the following day, the beads were extensively washed and
boiled in SDS-PAGE loading buffer. Eluted immunoprecipitates were
separated on 8-10% SDS-PAGE gels and immunoblotting was carried
out as described above.
2.5. Flow cytometry analyses
For ﬂow cytometry analyses, 5 × 105 cells were cultured in 6-well
plates and treated as required. Cells were then harvested, washed
twice in cold PBS containing 0.5% FBS, ﬁxed in 4% paraformaldehyde,
and permeabilized in 5% FBS containing 0.2% Triton X-100 and 0.5%
glycine. Cells were washed in PBS containing 0.1% horse serum and
incubated on ice for 1 h with anti-MOR antibody (1:1000) in PBS
containing 5% normal goat serum. Cells were washed and then incubat-
ed for 45 min with 1 μg of goat-anti-rabbit Alexa Fluor 488 in the same
buffer condition as the anti-MOR antibody. Cells were washed twice,
and 10,000 events were analyzed on a ﬂow cytometer (FACScalibur,
BD biosciences). For background subtraction, unstained cells and cells
stained with secondary antibody were also included.
2.6. Chromatin immunoprecipitation (ChIP) assays
Chromatin immunoprecipitation assayswere performed as reported
previously [34]. Brieﬂy, chromatin complexes were crosslinked by the
addition of 1% formaldehyde to treated cells. Cells were lysed (25 mM
HEPES, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP-40, 1 mM DTT, 0.5 mM
PMSF, and protease inhibitors) to isolate nuclei. Nuclei were
re-suspended in sonication buffer (50 mM HEPES, 140 mM NaCl,
1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
and protease inhibitors) and sonicated (Vibra-cell Sonicator) to isolate
chromatin. Puriﬁed chromatin was quantiﬁed, 1–5 μg of speciﬁc anti-
bodies were added to the puriﬁed chromatin, and the mixture was on
a rotating platform overnight 4 °C. Protein G Dynabeads (Invitrogen)
pre-blocked with salmon sperm DNA and BSAwere added, and incuba-
tion continued for 3 h at 4 °C to capture the immune complexes. The
beads were extensively washed in series of low- and high-salt washbuffers and Tris-EDTA buffer. The immune complexes were eluted,
decrosslinked, and treated with RNase and proteinase K. Finally, DNA
was puriﬁed from the eluate by phenol–chloroform–isoamyl alcohol
extraction and ethanol precipitation. Each immunoprecipitated DNA
sample was analyzed by real-time qPCR using the speciﬁc PCR primers.
ChIP assays were repeated at least three times for each antibody used.
2.7. Statistical analysis
Numerical values were presented as the mean ± S.E.M. For com-
parison between two samples, t-test analysis was performed. For
multiple comparisons, analysis of variance with Bonferroni's post
hoc test was used. *, p b 0.05 was considered statistically signiﬁcant
unless stated otherwise.
3. Results
3.1. JNK inhibition increases MOR gene expression.
In our previous study [20], we observed that treatment of
MOR-negative P19 cells with JNK inhibitor SP600125 (SP) signiﬁcantly
increased MOR gene expression. To examine the role of various inhibi-
tors on MOR gene expression, we treated P19 cells with SP, SB203580
(SB, a p38 MAPK inhibitor), LY294002 (LY, a PI3-K inhibitor), U0126
(a MEK1/2 inhibitor), and 6-amino-4-(4-phenoxyphenylethylamino)
quinazoline) (QNZ, a NF-κB transcriptional activation inhibitor) for
6 h and analyzed MOR expression by RT-PCR (Fig. 1A). Only SP signiﬁ-
cantly increased the level ofMORmRNA(Fig. 1A, lane 2), whereas treat-
ment with LY or QNZ caused minor changes in MOR levels (Fig. 1A,
lanes 4 and 6). To determine whether SP's effect on MOR gene expres-
sion is a dose-dependent response, we treated P19 cells with various
concentrations of SP for 6 h and analyzed the RNA by RT-PCR
(Fig. 1B). At 10 μM SP, an ~4-fold increase in MOR expression was ob-
served; the effect was clearer with 25 μM SP, which caused an ~7-fold
increase (Fig. 1B). A time-course experiment with 25 μM SP showed
an increase in MOR gene expression as early as 4 h (~3-fold, Fig. 1C).
At later time points, MOR expression increased, and expression
remained elevated until 48 h of treatment (data not shown). To test
whether JNK inhibition by speciﬁc peptide inhibitor could also increase
the MOR expression, P19 cells were incubated with increasing doses of
JNK-inhibitory peptide (JIP) for 6 h and MOR gene expression was
analyzed using qRT-PCR (Fig. 1D). A small increase (~1.7-fold) in MOR
gene expression consistently occurred in cells treated with JIP com-
pared with those treated with the control peptide (Fig. 1D). In order
to identify the speciﬁc JNK isoform involved, we transfected P19 cells
with siRNA against JNK-1, JNK-2 or both, and analyzed theMOR expres-
sion patterns (Fig. 1E, left panel). Knock-down of JNK-1 (Fig. 1E, right
panel) showed a small increase in MOR expression (~1.7-fold, Fig. 1E
left panel, lane 2) compared to the control (Fig. 1E left panel, lane 1),
a result which was comparable to the MOR expression levels induced
by JIP. However, JNK-2 knock-down did not increase the MOR expres-
sion levels, and knock-down of both JNK isoforms failed to further
enhance the MOR expression level beyond that obtained with JNK-1
siRNA transfected cells (Fig. 1E, left panel, c.f. lanes 1, 2 and 4). In addi-
tion, when SP was treated to the JNK siRNA transfected cells,
MOR expression levels were increased, which was comparable with
SP-treated wild type P19 cells (data not shown). Collectively, these re-
sults suggested that the inhibition of JNK-1 can increase MOR expres-
sion in P19 cells, and SP may use other mechanisms in addition to JNK
inhibition that leads to increased MOR expression.
To assess whether MOR gene expression in response to SP can be
observed in other cell types, we treated NMB neuroblastoma cells for
6 h with various concentrations of SP and performed semi-quantitative
RT-PCR analysis (Fig. 2A). Indeed, a small increase in MOR gene expres-
sion occurred in cells treatedwith 10 μMor 25 μMSP. To further analyze
the effect of SP on MOR expression in primary neurons, we treated
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of SP for 6 h and performed qRT-PCR (Fig. 2B). A dose-dependent
response to SP occurred, and 10 μM SP caused an ~2-fold increase in
MOR gene expression. These results show that JNK inhibitor SP causes
an increase in MOR gene expression in neuronal cells, although the
changes are smaller than in P19 cells.
SP has previously been shown to suppress Cdk1 and induce
endoreplication directly from G2 phase, resulting in polyploid cells
[35]. Another study showed that SP induces defective cytokinesisand enlargement of P19 cells [36]. These results could be used to
argue that the SP-induced increase in MOR expression is caused by
the presence of increased DNA content and increased stability of the
MOR mRNA. To rule out these possibilities, NMB cells (MOR-positive
cells) were treated with actinomycin-D (act-D, a transcription inhib-
itor) in the presence or absence of SP, and the amount of MOR mRNA
remaining at various time points was estimated. As shown in Fig. 2C,
the degradation pattern of MOR mRNA followed a similar course in
the presence or absence of SP (c.f. lanes 5, 6, 7 and 11, 12, 13). Because
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of NMB cells, and because SP could increase expression of MOR in
P19 cells as early as 4 h (Fig. 1C), as opposed to the 24 h needed to
attain polyploid cells, it appears that SP-mediated MOR increase
was due to active transcription of the MOR gene.
Because the treatment of P19 cells with SP signiﬁcantly increased
MOR at the transcript level, wewanted to examinewhether the protein
was also increased. P19 cells were treated with SP (25 μM), and MOR
expression patterns were analyzed by ﬂow cytometry. P19 cells
expressed low levels of MOR protein, whichwere increased by SP treat-
ment (Fig. 3A). The mean ﬂuorescent intensity (corresponding to the
MOR signal level) was increased by ~3-fold in SP-treated cells. These
results conﬁrm that SP treatment increases both MOR mRNA and pro-
tein expression.
3.2. p38 MAPK is involved in the increased expression of MOR by SP.
It has been demonstrated that JNK inhibition by SP can
activate CREB via the p38 MAPK-dependent pathway, leading to
increased expression of CREB responsive genes [37]. SP increasesthe transcriptional activation of p21 in an ERK-dependent pathway
that causes increased phosphorylation and binding of SP1 to the
p21 promoter [38]. In cerebellar granular cells, SP protects cells
from serum/potassium withdrawal-induced apoptosis, a phenome-
non that is mediated through phosphorylated (activated) AKT [39].
To examine the involvement of these signaling pathways in MOR
transcriptional regulation, we treated P19 cells with 25 μM of SP
for various lengths of time and performed western blotting with
anti-phospho-p38 MAPK, anti-phospho-AKT, and anti-phospho-ERK
1/2 antibodies. SP treatment increased the levels of phospho-p38
MAPK as soon as 15 min, and it remained elevated until 2 h of SP
treatment, whereas the levels of phospho-AKT were unchanged
(Fig. 4A). Interestingly, the activation of ERK 1/2 followed a biphasic
response. At 15 min post-SP treatment, a decrease in the ERK 1/2 phos-
phorylation occurred followed by a gradual increase over the 2 h treat-
ment. These results suggested that SP treatment is able tomodulate p38
MAPK and ERK 1/2 pathways in P19 cells. Since we could not detect
phospho-JNK or phospho-c-jun (downstream of JNK pathway) in P19
cells; as a control for SP’s activity, HEK 293 T cells were treated with
SP and immunoblotting was performed to detect changes in the levels
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1481Y. Wagley et al. / Biochimica et Biophysica Acta 1833 (2013) 1476–1488of phospho-c-jun. As expected, the levels of phospho-c-junwas reduced
by SP treatment of HEK 293 T cells (data not shown). In the next set of
experiments, we pretreated P19 cells with SB, wortmannin (a PI3-K/
AKT inhibitor), U0126, and act-D followed by 6 h of SP treatment in
order to identify whether p38 MAPK, PI3-K/AKT, ERK pathways tran-
scriptionally regulateMORgene expression in response to SP treatment.
RT-PCR analyses (Fig. 4B) showed that SB completely inhibited the
SP-mediated increase in MOR (~80% reduction in MOR expression
level compared to SP alone, Fig. 4B, lanes 2 and 3), and wortmannin
also showed a small decrease in MOR levels (~30% reduction compared
to SP alone, Fig. 4B, lane 4). U0126 treatment had little effect suggesting
that ERK pathway is not implicated in this response. Treatment with
act-D also reversed the increase in MOR mRNA, conﬁrming that the re-
sponse to SP treatment involves an increase in transcription. When we
pretreated the cells with a range of SB concentrations (2.5 μM–25 μM),
a dose-dependent reduction of MOR expression occurred, and 5 μM SB
returnedMOR expression to near baseline level (Fig. 4C, lanes 1, 2 and 4).
As stated earlier, JNK inhibition by SP can activate CREB via a p38
MAPK-dependent pathway leading to an increased expression of CREB
responsive genes [37]. Indeed, the MOR proximal promoter contains a
CREB binding site that is conserved in mouse, rat and human MOR
genes [19]. To determine if CREB is activated in the nucleus of P19 cells,
we performed immunoblots with nuclear protein from SP-treated P19
cells. CREB was not activated by SP treatment, although it was highly ac-
tivated by 1 h of 10 μM forskolin treatment as a positive control (Fig. 4D,
last lane). Additional RT-PCR experiments with forskolin and SP in P19
cells did not show an increase in MOR expression levels; instead,
forskolin treatment alone showed a slight decrease in MOR mRNA
(data not shown), conﬁrming that CREB is not involved in regulation of
MOR in P19 cells.
3.3. NF-κB is involved in the increased expression of MOR upon JNK
inhibition.
To ﬁnd the region of MOR promoter and the downstream factors of
p38 MAPK pathway that mediate the MOR expression in P19 cells in
response to SP treatment, we performed luciferase assays with MOR
promoter construct. Upon SP treatment, activity of the MOR promoter
construct containing the core promoter region (−450 bp/+1) in-
creased about 2.5-fold compared to the control (Fig. 5A, lower panel).
The binding sites for transcription factors in the core promoter region
of MOR gene (−450 bp/+1) contains NRSE [34,40], CREB [19], NF-κB
[18], Sp1/iGA [14], AP2/SP1 [15], and PCBP [13] elements (Fig. 5A,
upper panel). To further delineate whether NF-κB is responsible for
increased MOR expression in response to SP treatment, we pretreatedP19 cells with SB, U0126, and NF-κB inhibitors QNZ and PDTC and
then performed the luciferase assay. The increased activity of the MOR
promoter upon SP treatment could be reduced by SB, QNZ and PDTC
pretreatment, but not by U0126 pretreatment (Fig. 5A, lower panel).
This result suggested that p38 MAPK and NF-κB factors are important
for MOR expression in response to SP treatment. To further identify
the role of NF-κB for MOR gene expression in response to SP treatment,
we pretreated P19 cells with various doses of QNZ (1 nM−20 nM) and
performed RT-PCR analysis. A dose-dependent decrease inMORexpres-
sion occurred, and 10 nM QNZ signiﬁcantly inhibited MOR expression
(Fig. 5B, c.f. lane 5 with lane 2, ~60% decrease in expression compared
to SP alone). Similar results were obtainedwith a different NF-κB inhib-
itor, PDTC (data not shown), which further support our observation
that NF-κB is an important downstream factor in SP-mediated MOR
expression.
The classical pathway of NF-κB activation involves the phosphory-
lation and ubiquitin-mediated degradation of IkappaBalpha proteins
followed by increased nuclear translocation of NF-κB proteins and in-
creased transcriptional activation of responsive genes [41]. To analyze
whether SP treatment activates the NF-κB in this fashion, we analyzed
the extracts of SP-treated cells against phospho-IkappaBalpha antibod-
ies. However, we could not observe increase in the phosphorylation of
IkappaBalpha beyond the basal level (Supplementary Fig. A). Also, the
analysis of the NF-κB subunit proteins, p65 and p50, in the cytosolic
and nuclear proteins of SP-treated cells did not show signiﬁcant
changes in either cell compartments upon SP treatment (Fig. 5C). Of
note, signiﬁcant amounts of p65 and p50 proteins were constitutively
present in the nuclear fraction of P19 cells under non-stimulated condi-
tions (Fig. 5C). Since the transactivation ability of NF-κB is increased by
phosphorylation of p65 subunit, we analyzed whether SP treatment
changes the phosphorylation status of p65 subunit of NF-κB. Using
two known phospho-speciﬁc p65 antibodies (S536 and S276), we
performed western blots with protein extracts from the cytosolic and
nuclear fraction of SP-treated cells. As shown in Fig. 5D, we did not
observe any phosphorylation of p65 in the cytosolic pools but the phos-
phorylation of phospho-p65 (Ser 536) increased in the nuclear fraction
upon SP treatment; and it could be abrogated by SB pretreatment
(Fig. 5D). Analysis of the phosphorylation of p65 at another residue,
Ser 276 also showed a small increase upon SP treatment which was
not decreased by SB pretreatment (Fig. 5D, lower panel). These results
suggested that the SP-mediated increase in phosphorylation of p65
(Ser 536 and Ser 276) speciﬁcally occurs inside the nucleus, and that
the Ser 536 phosphorylation of p65 is dependent on p38MAPK activity.
To further verify that p65 is involved in the upregulation ofMOR gene
expression in response to SP treatment; we employed knock-down
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1482 Y. Wagley et al. / Biochimica et Biophysica Acta 1833 (2013) 1476–1488strategy using siRNA. P19 cells were transfected with control siRNA or
p65 speciﬁc siRNA for 36 h and then treated with SP for 6 h (Fig. 5E).
RNA and total cell lysates were then extracted to perform RT-PCR
for MOR expression patterns and immunoblotting to assess p65
knock-down. As shown in Fig. 5E left panel, transfection of p65 siRNA
abolished the SP-induced MOR gene expression by ~50% compared to
the control siRNA transfected cells (c.f. lane 2 with lane 4), a result
which reﬂected the ~50% reduction of p65 proteins in the siRNA
transfected cells (Fig. 5E, right panel). As a control for speciﬁc activity of
the p65 siRNA, the p50 subunit of NF-κB was analyzed by immunoblot-
ting, and was found unaffected.In a previous study [42], it has been shown that theMAPK nuclear ki-
nase, mitogen-and stress-activated protein kinase 1 (MSK1), induces
NF-κB p65 serine 276 phosphorylation upon IL-1β treatment, as well
as MAPK inhibition abolishes binding of p65, of its coactivator CBP and
of MSK1 to the κB intronic enhancer site of the stem cell factor gene.
Our results also indicated a minor increase in S276 phosphorylation of
p65 by SP treatment and that knock-down of p65 by siRNA abolishes
theMOR gene expression by SP (Fig. 5E), we testedwhetherMSK1 is in-
volved in theMOR gene activation. Therefore, P19 cells were pretreated
with increasing concentrations of H89 (aMSK1-PKA inhibitor) followed
by SP treatment for 6 h. Semi-quantitative and quantitative RT-PCR
1483Y. Wagley et al. / Biochimica et Biophysica Acta 1833 (2013) 1476–1488results showed that inclusion of H89 indeed decreased the SP-induced
MOR gene expression in a dose-dependent fashion (Fig. 6A). To analyze
whether activated/phosphorylated MSK1 and p65 interacted in the
nucleus of P19 cells, the nuclear fractions of SP-treated cells were
immunoprecipitated with anti-p65 antibody and subjected to immuno-
blotting with anti-phospho-MSK1 antibody. As shown in Fig. 6B,
phosphorylated MSK1 and p65 had a minimal interaction under
non-stimulated conditions (lane 1), and the interaction increased after
1 h of SP treatment (lane 2) which increased further at 2 h and 4 h
post-SP treatment (lanes 3 and 4) suggesting that p38 MAPK/MSK1
pathway may also be involved in the MOR gene expression upon SP
treatment.
Because the MOR promoter in un-stimulated P19 cells resembles a
closed chromatin structure [32], we analyzed several epigenetic tags
and co-activators of NF-κB that are changed in the activeMOR promoter
upon SP treatment (Fig. 6C). Binding of CBP (a co-activator of NF-κB) to
the MOR promoter increased upon SP treatment along with the in-
creased histone 3-dimethyl lysine 4 (a hallmark of active transcription),
while showing decreased bindings of histone 3-trimethyl lysine 9
(a hallmark of repressive transcription), HDAC-2, and MeCP2 (protein
that binds to methyl CpG islands and blocks transcription) [32,33] at
the MOR promoter region. These results suggest that SP treatment,
along with the activation of p38 MAPK and NF-κB activation, is able toA
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of MOR gene.
3.4. Two major factors, p38 MAPK and NF-κB are also associated with
MOR gene expression in neuronally differentiating P19 cells
Neuronal differentiation of P19 has been used as an excellent
model to investigate the MOR gene expression [32,33,43,44]. During
retinoic acid induced neuronal differentiation of P19 cell, MOR gene
expression starts to increase by 2 days after plating (P19-AP2D),
and maximum expression is observed at 4 days (P19-AP4D), when
the cells differentiate into neuronal cells [32,33]. As reported previ-
ously, we observed a similar pattern of MOR expression (~70-fold
and ~200-fold on day 2 and day 4, respectively, compared with undif-
ferentiated P19 cells) [33]. Therefore, we used this model to examine
whether the p38 MAPK and NF-κB pathways are important for MOR
gene expression during neuronal differentiation of P19 cells.We treated
differentiating P19 cells at day 2 (P19-AP2D) with various inhibitors
and examined MOR levels the following day by semi-quantitative
RT-PCR and real time RT-PCR.We chose longer treatment times because
the half-life of MOR mRNA as shown by act-D treatment in NMB cells
was ~9 h (Fig. 2C, lanes 1 and 11). As expected, treatment with SB
and NF-κB inhibitors QNZ and PDTC signiﬁcantly decreased MOR levelsB
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1484 Y. Wagley et al. / Biochimica et Biophysica Acta 1833 (2013) 1476–1488(~50–60% decrease comparedwith the control cells; Fig. 7B, lanes 1, 3, 6
and 7), whereas wortmannin and U0126 treatments showed no effect
(Fig. 7B, lanes 1, 4 and 5). These results are consistent with those
obtainedwith undifferentiated P19 cells, where SB andNF-κB inhibition
signiﬁcantly inhibited MOR expression induced by SP (Figs. 4B, C, 5B
and E). However, SP treatment in the differentiating neurons led to
only a small increase in MOR expression (~2-fold) (Fig. 7B, lanes 1
and 2, 16 h) compared with the ~12-fold increase in undifferentiated
P19 cells (Fig. 1C, lanes 1 and 9, 16 h) suggesting that the p38 MAPK
and NF-κB pathways are already activated in the differentiating neuro-
nal cells, and thus, SP’s effect on MOR expression in these cells may be
less noticeable. Again, this result is consistentwith SP's reduced potency
in NMB neuroblastoma cells (Fig. 2A) and rat primary hippocampal
neurons (Fig. 2B), cells types that constitutively express MOR gene.
Indeed, the immunoblot analysis of active MAPKs in differentiating
P19 cells showed that p38 MAPK is activated by day 1 after plating
and continues to increase further as the cells begin to differentiate(Fig. 7C). In addition to the p38 MAPK, activation of ERK1/2, AKT and
JNK pathways were also observed in differentiating P19 cells with the
maximal activation observed at days 1, 2 and 3 respectively after plating
(Fig. 7C). As a control for the neuronal differentiation of cells, the
expression of neuronal speciﬁc HuB/HuD proteins were analyzed and
found to be continually increased after plating (Fig. 7C).
4. Discussion
MOR gene expression has been shown to be regulated by fentanyl,
morphine, IL-1, lipopolysaccharide, protein synthesis inhibitors (such
as cycloheximide, anisomycin and puromycin), demethylating agents,
histone deacetylase inhibitors and dopaminergic drugs such as
cocaine and haloperidol [19,20]. With such a diverse group of sub-
stances regulating the MOR gene, many regulatory elements have
been shown to interact at the MOR promoter and positively or nega-
tively affect the expression of the MOR gene (see Introduction for
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1485Y. Wagley et al. / Biochimica et Biophysica Acta 1833 (2013) 1476–1488details). In this study, we show the transcriptional regulation of the
MOR gene by JNK inhibition. In P19 embryonal carcinoma cells,
NMB neuroblastoma cells, and primary hippocampal neurons, JNK
inhibition by SP600125 led to increased MOR expression. This
increase was reversed by inhibition of the p38 MAPK pathway. The
use of synthetic inhibitors and activators of multiple pathways sug-
gests an important role of NF-κB in upregulation of the MOR gene.
Corresponding to the ﬁndings in undifferentiated P19 cells, MOR
transcription was regulated by p38 MAPK and NF-κB pathways in
P19 cells undergoing retinoic acid induced neuronal differentiation.
P19 cells can be terminally differentiated into neuronal cells by
retinoic acid treatment, a process that closely resembles neurogenesis
of mammalian CNS cells [45]. Analysis of the activation of MAPK path-
ways during P19 neuronal differentiation has shown that activation
of the ERK and p38 MAPK pathways occur at day 1 and day 2 after
plating, respectively, but the JNK pathway is not activated until
7 days after the induction of differentiation [45–47]. In addition, the
p38/MEF2 pathway has been shown to prevent cell death during neu-
ronal differentiation [45]. MOR gene expression during P19 neuronal
differentiation occurs 2 days after plating, when the p38 MAPK path-
way is also activated [33,47]. Our data, showing that inhibition of p38
MAPK by SB could reduce MOR transcript levels in differentiating P19cells (Fig. 7B, lanes 1 and 3), correlates with the activation kinetics of
p38 MAPK and MOR gene expression. The ERK pathway is not
involved in MOR expression during neuronal differentiation of P19
cells, because inhibition of the MEK pathway had no effect on MOR
expression. Also, neuronal differentiation of P19 cells occurs with
extensive chromatin remodeling accompanied by the dissociation of
MeCP2 from, and association of Brg1 and BAF155 with, the proximal
promoter [33]. At present, it is uncertain whether signaling through
the p38 MAPK pathway is involved in the epigenetic changes that
occur at the MOR promoter during neuronal differentiation.
In a recent in vivo study, nerve growth factor was shown to increase
the number of phosphorylated p38 MAPK immunoreactive neurons ex-
pressingMOR indorsal root ganglia, increase peripherally directed axonal
transport of MOR, and increase signiﬁcant potentiation, as well as en-
hance efﬁcacy in fentanyl- and buprenorphine-induced dose-dependent
antinociception [48]. The expression of MOR gene in P19 cells by protein
synthesis inhibitors is mediated through the activation of the PI-3K and
p38 MAPK pathways, and inhibiting p38 MAPK decreases the constitu-
tively expressed MOR expression levels in NMB neuroblastoma cells
[20]. These results are consistent with the ﬁndings of our study, which
show that MOR expression induced by SP treatment of P19 cells is
blocked by p38 MAPK inhibition (Fig. 4B, and C). Although the JNK
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scriptional activity, several studies have shown antagonism between
these pathways [49]. For example, genetic ablation or chemical inhibi-
tion of p38 MAPK has been shown to activate JNK [49,50], and JNK
inhibition by SP has been shown to activate p38 MAPK [37]. Therefore,
the opposing regulation of these two pathways observed in our system
should exist at the level of an upstream MAP3K which is supported by
the fact that upstream kinase mediated phosphorylation of p38 MAPK
is not inhibited by SB [51]. Correspondingly, SB pretreatment had no ef-
fect on the phosphorylation status of p38MAPK elicited by SP treatment
(supplementary Fig. B). In a different study, TNF-α-mediated human
MOR gene expression in immune and neuronal cells involved NF-κB
binding; independent of AP-1 activity [18]. JNK activation, an important
event for AP-1 mediated transcription, involves dimers of the c-Jun and
fos family of transcription factors. In line with this concept, our results
showing the p38 MAPK- and NF-κB- dependent expression of the
MOR gene upon JNK inhibition agree with the ﬁndings that NF-κB but
not AP-1, is involved in the regulation of human MOR gene. It has
been reported that in multiple myeloma cells, SP can induce NF-κB ac-
tivation in a dose-dependent manner, associated with phosphorylation
of IkappaB kinase alpha (IKKalpha) and degradation of IkappaBalpha
[52]. Contrary to this ﬁnding, we observed that the phosphorylation ofIkappaBalpha did not increase beyond baseline level upon SP treatment
(Supplementary Fig. A). In addition, the NF-κB subunit p65 protein is
constitutively present (Fig. 5C), and p38 MAPK-dependent phosphory-
lation of p65 speciﬁcally increased in the nucleus of P19 cells upon SP
treatment (Fig. 5D), suggesting a different mode of NF-κB activation in
our system. Since p38 MAPK does not contain a consensus phosphory-
lation site within p65; it, therefore, seems probable that other second-
ary kinases may be involved in the p65 phosphorylation. One of
them may be the PI-3K/AKT. Although the levels of activated AKT did
not change upon SP treatment (Fig. 4A), the level of MOR expression
was reduced by ~30% in wortmannin pretreated cells (Fig. 4B), and
PI-3K/AKT inhibition by LY treatment reduced the basal MOR expres-
sion levels in P19 cells (Fig. 1A) suggesting PI-3K/AKT as one of the
possible candidates that manifest the NF-κB transactivation activity in
P19 cell system. In support of this notion, previous reports have
shown that the transactivation ability of p65 is stimulated by the
cross-talk between PI-3K/AKT/p38 MAPK pathways [53,54]. Alterna-
tively, nuclear kinase of MAPKs, MSK1 may be considered another
kinase that regulated p65 transactivation. As shown in Fig. 4A, besides
sustained increase of p38MAPK activation, ERK activation was gradual-
ly increased after initial downregulation upon SP treatment. Both of
these kinases are well-known to activate nuclear kinase MSK1 [42,55],
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transactivation potential. In addition, MSK1 is also known to phosphor-
ylate histone proteins that aids in the modiﬁcation of chromatin struc-
ture and facilitate the binding of transcription factors [56]. Although
we did not observe a dramatic increase in Ser 276 phosphorylation by
SP treatment, the interaction of p65 with active MSK1 was found to be
increased in the nucleus of SP-treated cells (Fig. 6B). It may be possible
that the basal phosphorylation of p65 at Ser 276 associated with the
histone modiﬁcations by MSK1 co-operated for MOR gene expression.
Currently, we are performing experiments to determine whether acti-
vatedMSK1 is able tomodify chromatin structure at theMOR gene pro-
moter and increase MOR expression. Apart from this, it is also possible
that post-translational modiﬁcation of p65 such as acetylation, and
p65 phosphorylation by kinases such as protein kinase A (PKA), protein
kinase C ζ (PKCζ), casein kinase 2 (CK2), and ribosomal S6 kinase
(RSK1) at different serine residues such as Ser 311, Ser 529 [57] may
have accounted to increase MOR gene expression. Nonetheless, the de-
ﬁnitive role of p65 in MOR gene expression upon SP treatment of P19
cells is established by the fact that knock-down of p65 expression
blocked MOR gene expression (Fig. 5E). Among the six putative NF-κB
binding sites on the human MOR gene promoter, three sites located at
−2194, −557 and −207 positively regulate MOR expression in re-
sponse to TNF-α [18]. However, results from the luciferase assay in
our system using the core-promoter region (−450 bp/+1) indicated
an ~2.5-fold activation (Fig. 5A, lower panel), suggesting that the prox-
imal NF-κB site is enough to increase the MOR gene expression in re-
sponse to SP treatment. Although it is not analyzed in this study, it is
possible that transcription factors such as SOX-18, SP1, and PCBP1
(which were shown to be dependent on the AKT and p38 MAPK path-
ways in response to cycloheximide treatment in P19 cells) bound to a
different region of the MOR promoter and co-operated to increase
MOR expression upon JNK inhibition [20]. Nevertheless, the expression
of the MOR gene by JNK inhibition is important in the context of pain
perception and opioid antinociception, as discussed below.
Among the MAPK family members, ERK and p38 MAPK have
well-documented roles in regulating neuronal plasticity and nocicep-
tive pathway via glial and neuronal mechanisms [21,58]. In recent
years, JNK activation, apart from its known involvement in cell prolif-
eration, differentiation and inﬂammatory responses, has gained an at-
tention towards nociception and opioid systems [49]. For example,
transient activation of JNK can be seen in DRG neurons followed by
a persistent activation in the spinal cord after spinal nerve ligation
[21]. Also, NMDA receptor-dependent phosphorylation of ERK, p38
MAPK and JNK in the spinal cord and DRG occurs in rats with
streptozotocin-induced diabetes, and the mechanical hyperalgesia as-
sociated with diabetic neuropathic pain can be reversed by blocking
MAPK or with an NMDA antagonist [59]. Additionally, chronic mor-
phine treatment activates JNK in SH-SY5Y cells [24,25], T cells [26],
and spinal cord [27]. In a rat model, single or chronic morphine injec-
tions induce JNK-3 mRNA in the frontal cortex, and following cessa-
tion of morphine treatment, sustained elevation of JNK-3 is found in
the hippocampus and thalamus, where the chronic morphine treat-
ment previously have had no effect [28]. Moreover, receptor signaling
is disrupted by activated JNK in response to long-acting κ opioid
antagonist [60] as well as MOR desensitization, and acute analgesic
tolerance to morphine and related opiates is blocked by JNK inhibi-
tion [27,29]. Collectively, these results indicate that JNK activation
has a negative role in neuropathic pain prognosis and opioid pharma-
cology. JNK inhibition, therefore, seems to have two positive effects
on opioid therapy and neuropathic pain management. First, in the
case of morphine tolerance observed by receptor densensitization
and downregulation, a continuous supply of newly synthesized
receptors by JNK inhibition may transmit adequate antinociceptive
signals. In support of this notion, a recent study demonstrated that
acute morphine tolerance can be avoided by inhibiting JNK [29]. Sec-
ond, based on the observation that JNK is activated in neuropathicpain models and that JNK inhibition can reverse pain hypersensitivity,
blocking JNK activation is likely to exert positive effects on long-term
pain management. It remains to be determined, how/whether intrinsic
pain response factors are modulated by JNK.
In conclusion, we demonstrate that JNK inhibition stimulates MOR
gene expression and that this stimulation is blocked by inhibitors of
p38 MAPK and NF-κB pathways. The results of our study suggest
that because inhibition of p38 MAPK and NF-κB contribute to the
downregulation of MOR expression levels in differentiating neuronal
cells, strategies to activate p38 MAPK and NF-κB in the neurons, pos-
sibly by including JNK inhibitor in an opioid treatment regimen, could
be used to increase receptor numbers and the effectiveness of opioid
treatment.
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